Baxter (BAX) Tops Q1 EPS by 7c; raises guidance
Tweet
Share
E-mail
Get Alerts BAX Hot Sheet
Price: $27.05 --0%
Financial Fact:
Research and development expenses: 159M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Financial Fact:
Research and development expenses: 159M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Join SI Premium – FREE
Baxter (NYSE: BAX) reported Q1 EPS of $0.55, $0.07 better than the analyst estimate of $0.48. Revenue for the quarter came in at $2.63 billion versus the consensus estimate of $2.59 billion.
GUIDANCE:
Baxter sees Q2 2025 EPS of $0.59-$0.63, versus the consensus of $0.61.
Baxter sees FY2025 EPS of $2.47-$2.55, versus the consensus of $2.49.
For earnings history and earnings-related data on Baxter (BAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
- Evolv Technology adds 70 customers in Q2, expands bag screening
- Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
